These shares have doubled over the past 30 days advancing from $0.12 cents to over $0.24 cents and trading at 5 times their average 30 day volume . With 57 million closely held shares outstanding these shares have great upside potential . All serious investors should consider placing SONA on their buy list
Fast track applications with FDA and Health Canada for an instant Coronavirus blood test are being prepoared with the trial about to commence.
Sona Nanotech Inc. is a nanotechnology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market.Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.
Sona Announces Data Partnership for Covid-19 Rapid Screening TestHalifax, Nova Scotia–
(Newsfile Corp. – February 18, 2020) – Sona Nanotech Inc. (CSE: SONA) has announced a partnership with UK-based medical technology company Bond Digital Health (Bond) to add data capture and analysis to its coronavirus (Covid-19) rapid screening test currently in development.
This data partnership will allow test result data to be collected through either a reader system or mobile app before being securely stored in the cloud. The data can be accessed and analyzed on an analytics dashboard, providing feedback on:The total number of tests administered
Positive and negative resultsGeolocation of where tests are administeredDemographic information of patients (when input)When fully deployed, the captured data could ultimately allow the spread of the outbreak to be monitored, with increasing or decreasing trends mapped in real time.
Bond, based in Cardiff in the United Kingdom, offers the only known proprietary digital data capture and analysis services specifically for lateral flow devices. Bond’s data platform offers industry leading data security and is fully compliant with all relevant regulations, making Bond a key partner for this project.Sona Nanotech CEO Darren Rowles said, “Adding Bond alongside Native Antigen to the consortium developing the Covid-19 rapid response test will significantly improve the value and functionality of the test for the medical community, helping authorities detect, manage and control the spread of this outbreak.”Phil Groom, Commercial Director of Bond Digital Health, said, “The Covid-19 outbreak demonstrates the urgent global need for digitally connected, data-driven rapid diagnostic test systems. Sona Nanotech’s proprietary nanotechnology has already demonstrated exceptional levels of sensitivity in tests compared to other commercially available particles. This, combined with the team’s expertise and experience in the lateral flow market, makes Sona the perfect company to drive this project forward. We are proud to be partnering with Sona Nanotech on such a crucial project.”Covid-19 was first detected in Wuhan, Hubei Province, China at the end of December. Sona expects to provide continuing updates on its Covid-19 rapid test development in the near term.
About Sona Nanotech Inc.
Sona Nanotech Inc. is a nanotechnology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market.Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.
Sona is a publicly listed company on the Canadian Securities Exchange existing under the laws of Nova Scotia, with its operations in Nova Scotia.
About Bond Digital Health
Based in Cardiff, Wales, UK, Bond Digital Health Ltd is the only company in the world offering bespoke digital products and services specifically for lateral flow devices. Bond is digitising an entire industry and helping with global efforts to decentralise health testing. Bond has developed a white label digital platform for lateral flow technologies, called Transform™. Featuring app development, cloud data management and real-time analytics dashboard, Transform™ offers secure cloud connectivity and is fully regulated and compliant with medical device software regulations.
FORWARD-LOOKING INFORMATIONThis press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company’s current expectations. When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information.
There are several important factors that could cause the Company’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others, risks related to Sona’s proposed business, such as failure of the business strategy and government regulation; risks related to Sona’s operations, such as additional financing requirements and access to capital, reliance on key and qualified personnel, insurance, competition, intellectual property and reliable supply chains; risks related to Sona and its business generally, such as infringement of intellectual property rights and conflicts of interest. The Company cautions that the foregoing list of material factors is not exhaustive. When relying on the Company’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company has assumed a certain progression, which may not be realized. It has also assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. While the Company may elect to, it does not undertake to update this information at anytime
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.
|
